MEGAKARYOCYTE PROGENITOR CELLS FOR PRODUCTION OF PLATELETS

• US 20140205582A1
• Filed: 07/06/2012
• Published: 07/24/2014
• Est. Priority Date: 07/06/2011
• Status: Abandoned Application

• Current Assignee: Cellerant Therapeutics Incorporated
• Original Assignee: Cellerant Therapeutics Incorporated
• Inventors: Karsunky, Holger, Chanaukul, Chanawan, Pantuganti, Swapna
• Application Number:
  US14/130,894
• Publication Number:
  US 20140205582A1
• Time in Patent Office: Days
• US Class Current: 424/93.72
• CPC Class Codes: A61K 35/19 Platelets; Megacaryocytes
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: C12N 2501/145 Thrombopoietin [TPO]
• CPC Class Codes: C12N 2501/2301 Interleukin-1 (IL-1)
• CPC Class Codes: C12N 2501/2309 Interleukin-9 (IL-9)
• CPC Class Codes: C12N 5/0644 Platelets; Megakaryocytes

Abstract

Provided herein are methods of generating megakaryocyte lineage cells from hematopoietic stem cells in the absence of feeder cells and serum. The megakaryocyte progenitor cells (MKPs) generated as described result in rapid production of significant numbers of platelets when administered in vivo.

Claims

1. An isolated population of human cells comprising at least 40% CD34+CD41+ megakaryocyte progenitor cells (MKPs), wherein said population of cells has platelet generating activity, and wherein administration of 5×

10⁶ cells from the population of cells into an immunocompromised mouse results in at least 10⁶ human platelets/ml blood 14 days post-administration.

2. The isolated population of cells of claim 1, comprising at least 50% CD34+CD41+ MKPs.

3. The isolated population of cells of claim 1, wherein at least 50% of the CD34+CD41+ MKPs are CD184+.

4. The isolated population of cells of claim 1, wherein less than 60% of the CD34+CD41+ MKPs are CD42a+.

6. The isolated population of cells of claim 1, wherein the cells are derived from a plurality of individuals.

7. The isolated population of cells of claim 1, wherein the cells are cryopreserved.

8. The isolated population of cells of claim 1, wherein administration of 5×

10⁶ of the cells into an immunocompromised mouse results in at least 10⁷ human platelets/ml blood 14 days post-administration.

17. A pharmaceutical composition comprising the isolated population of cells of claim 1 and a pharmaceutically acceptable excipient.

18. The pharmaceutical composition of claim 17, wherein the composition is cryopreserved.

42. A method comprising

administering to an individual the pharmaceutical composition of claim 17, wherein the administering generates platelets in the individual.

5. (canceled)

9-16. -16. (canceled)

19. A method comprising:

culturing human CD34+ hematopoietic stem cells (HSCs) in media comprising thrombopoietin (TPO) or a TPO analog and IL-1 a under conditions that permit the CD34+ HSCs to generate a population of cells comprising CD34+CD41+ megakaryocyte progenitor cells (MKPs),

wherein administration of 5×

10⁶ cells from the population cells into an immunocompromised mouse results in at least 10⁶ human platelets/ml blood 14 days post-administration, thereby forming a population of cells comprising MKPs.

21. The method of claim 19, wherein the media further comprises HSA.

22. The method of claim 19, wherein the culturing is carried out in agitation conditions.

23. The method of claim 19, wherein the media does not include serum or feeder cells.

24. The method of claim 19, wherein the HSCs are obtained from a plurality of individuals.

25. The method of claim 19, wherein the HSCs have been cryopreserved.

20. A method comprising:

culturing human CD34+ hematopoietic stem cells (HSCs) in media comprising thrombopoietin (TPO) or a TPO analog, IL-1α

or IL-1β

, and IL-9 under conditions that permit the CD34+ HSCs to generate a population of cells comprising CD34+CD41+ megakaryocyte progenitor cells (MKPs),

wherein administration of 5×

10⁶ cells from the population cells into an immunocompromised mouse results in at least 10⁶ human platelets/ml blood 14 days post-administration, thereby forming a population of cells comprising MKPs.

45. The method of claim 20, wherein the media further comprises HSA.

46. The method of claim 20, wherein the culturing is carried out in agitation conditions.

47. The method of claim 20, wherein the individual and the MKPs have a mismatch at one or more MHC loci.

48. The method of claim 20, wherein the HSCs are obtained from a plurality of individuals.

26-41. -41. (canceled)

43-44. -44. (canceled)

49-53. -53. (canceled)